A Review of an Adjunct Clinical Symposium of the American College of Gastroenterology Meeting
October 16, 2016 • Las Vegas, Nevada
Abstract: Many nonpharmacologic and pharmacologic therapies are available to manage irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC). The American College of Gastroenterology (ACG) regularly publishes reviews on IBS and CIC therapies. The most recent of these reviews was published by the ACG Task Force on the Management of Functional Bowel Disorders in 2014. The key objective of this review was to evaluate the efficacy of therapies for IBS or CIC compared with placebo or no treatment in randomized controlled trials. Evidence-based approaches to managing diarrhea-predominant IBS include dietary measures, such as a diet low in gluten and fermentable oligo-, di-, and monosaccharides and polyols (FODMAPs); loperamide; antispasmodics; peppermint oil; probiotics; tricyclic antidepressants; alosetron; eluxadoline, and rifaximin. Evidence-based approaches to managing constipation-predominant IBS and CIC include fiber, stimulant laxatives, polyethylene glycol, selective serotonin reuptake inhibitors, lubiprostone, and guanylate cyclase agonists. With the growing evidence base for IBS and CIC therapies, it has become increasingly important for clinicians to assess the quality of evidence and understand how to apply it to the care of individual patients.
Evidence-Based Assessment of IBS/CIC Therapies: Setting the Stage
Irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC) are highly prevalent, heterogeneous functional disorders that are among the most common conditions seen by gas-troenterologists.1-3 Selecting app-ro-priate therapies for patients with these disorders is complicated by the heterogeneity of the pathogenic mech-anisms and patient populations, as well as the broad range of nonspecific symptoms that patients may experience.4,5 Accordingly, a broad range of nonpharmacologic and pharmacologic therapies are available to manage IBS and CIC, and a number of new therapies are currently under investigation. Understanding the current evidence regarding these therapies is important in guiding clinicians to the most appropriate therapy for their individual patients. To that end, several systematic reviews of therapies for IBS and CIC have been conducted.4,6-8
The American College of Gastroenterology (ACG) has published a number of reviews on IBS and CIC therapies over the past decade.6-9 The most recent of these reviews was published by the ACG Task Force on the Management of Functional Bowel Disorders in 2014.6 The key objective of these reviews was to evaluate the efficacy of therapies for IBS or CIC compared with placebo or no treatment in randomized controlled trials (RCTs). The primary outcome measure assessed for IBS and CIC therapies was any improvement of global IBS or CIC symptoms, respectively, whenever possible. Recommendations regarding treatments were graded using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system.6 According to this system, the quality of the evidence is assessed based on study design as well as potential for bias, inconsistency, indirectness, and imprecision.10 The quality of evidence is rated from very low to high, depending on the extent to which further evidence would change the estimate of the treatment effect (Figure 1).6 The strength of recommendations is graded as weak to strong based on the quality of evidence as well as its applicability to all patient groups, balance of benefits and risks, patient preferences, and cost.
Interpreting Study Design
A number of aspects are taken into account when evaluating the quality of study design. Randomization is the cornerstone of a clinical trial and is needed to reduce bias by ensuring a balanced distribution of potential confounding factors between treatment groups.11,12 This in turn helps ensure that differences in outcomes between treatment groups can be attributed to the effect of the treatment. For example, without randomization, the result of an IBS trial could be biased owing to a disproportionate number of patients with severe IBS in either treatment group. Given the subjective nature of functional bowel symptoms, appropriate masking and double-blinding is essential for IBS and CIC trials. For example, patients may be less likely to describe symptom improvement if they or the investigators know that they are receiving placebo treatment. Ensuring complete study follow-up and analyzing data according to intent-to-treat (ITT) principles are also important in ensuring the validity of trial results. ITT analysis avoids overstating the efficacy of an intervention by including every randomized subject regardless of noncompliance, protocol deviations, and/or withdrawal.13
Interpreting Key Measures of Treatment Efficacy
The impact of treatments reviewed by the ACG was expressed as a relative risk (RR) of IBS or CIC symptoms not improving and reported with 95% confidence intervals (CIs). RR is expressed as the ratio of the risk of symptoms not improving in the 2 groups, with a risk ratio of 1 indicating no difference between treatment groups.4 The RR reduction, calculated from 1 minus the risk ratio, represents the proportional reduction in risk in one treatment group compared with another.4 For example, an RR of 0.80 is interpreted as the probability of not achieving global symptom improvement being 20% compared with that without treatment. In other words, patients treated with the active therapy are 20% (100 × [1-RR]%) more likely to achieve symptom improvement compared with patients treated with placebo. The confidence interval (usually 95%) estimates the range of results that might be expected if the study were repeated frequently in the same setting.12 A narrow 95% CI indicates a more precise estimate of the treatment effect, whereas a wide CI indicates imprecision and can often be attributed to few events or relatively few patients.4,12
The number needed to treat (NNT) refers to the number of patients who would need to be treated with an active therapy, over and above the control therapy, for 1 to experience an improvement in symptoms.6 Although NNT values are helpful when comparing 2 active therapies, they are not as useful when comparing active treatment against placebo. To the contrary, comparing the NNT of treatments that have been evaluated in separate placebo-controlled RCTs can be misleading, as the NNT will vary based on differences in study duration, patient population, endpoint, and other key aspects of the study design.
Applying Evidence-Based Medicine to Practice
In order to critically appraise the evidence, clinicians must understand study limitations, recognize bias, extract information, and reach appropriate conclusions.14 However, it is important to recognize that the application of evidence-based medicine does not devalue clinical experience. To the contrary, successful evidence-based practice requires that clinicians apply the scientific findings to their clinical decision-making process for individual patients.11 The magnitude of benefit, risk of side effects, patient preferences, and cost for individual patients are all key aspects of clinical decision-making. However, clinical experience guides the clinician’s application of data to individual patients. The treatment nuances that clinicians learn over time is invaluable when applying evidence, and is also crucial when useful evidence is absent. Lack of evidence should not be construed as lack of efficacy. For example, the ACG monograph concluded that the quality of evidence for the use of probiotics in IBS is low and that the strength of the recommendation regarding their use is weak.6 Rather than concluding that all probiotics are ineffective, this indicates that the current evidence is insufficient to identify specific probiotics that are effective. In the future, well-designed research trials may identify effective probiotics or provide more definitive evidence that probiotics are not effective. Until those studies are performed, physicians should use their own clinical experience to decide when to use a probiotic and which probiotic to select. Similar recommendations were made for other therapies in IBS, including loperamide and polyethylene glycol.6 In scenarios such as these, characterized by a lack of evidence to guide therapy, clinicians must draw on their clinical experience when making treatment decisions.
Evidence-Based Approach to Managing IBS-D
Dietary Approaches
Although many patients with IBS believe that food sensitivity contributes to their symptoms,15 dietary therapy has not played a key role in IBS management, largely owing to historically poor evidence of its benefit.7,16 However, there appears to be renewed interest in the role of dietary manipulations in IBS, possibly owing to growing recognition of potential dietary triggers, such as gluten and fermentable oligo-, di-, and monosaccharides and polyols (FODMAPs), in some patients.5,17
Of 12 RCTs that evaluated dietary intervention in IBS, only 3 of these trials met the inclusion criteria and were evaluated by the ACG review (Table 1). This evidence was considered to be of very low quality, leading to the weak recommendation that dietary manipulation may improve symptoms in individual patients.6 Since the ACG review was conducted, however, results of the first RCT of the low FODMAP diet in patients with diarrhea-predominant IBS (IBS-D) in the United States have been published.18 In this single-center study, 92 patients were randomized to either a low FODMAP diet or a diet based on modified National Institute for Health and Care Excellence (mNICE) guidelines for 4 weeks. From 40% to 50% of patients reported adequate relief of their IBS-D symptoms with either diet, but the low FODMAP diet was significantly more effective in improving individual symptoms, particularly pain and bloating (Figure 2).
Loperamide
Despite its frequent use in clinical practice, very few controlled trials support the use of loperamide for IBS. Indeed, the evidence reviewed in the ACG monograph included 2 RCTs involving a total of 42 patients.6 These data were considered to be of very low quality, leading to the strong recommendation that there is insufficient evidence to support the use of loperamide in relieving abdominal pain, bloating, or global IBS symptoms.6 Despite this conclusion, however, loperamide continues to be used frequently in patients with IBS-D, underscoring the important role of experience-based medicine when there is a lack of evidence to inform clinical decision-making.
Antispasmodics
Antispasmodics have been used for decades for IBS based on their ability to relax smooth muscle in the gut.5,6 Based on 23 RCTs evaluating 2154 patients with IBS worldwide, the ACG monograph made a weak recommendation that certain antispasmodics can relieve symptoms in the short-term.6 However, of these studies, only 4 RCTs evaluated antispasmodic drugs that are available in the United States (hyoscine and dicyclomine). Thus, there is insufficient evidence to recommend the use of these particular agents for IBS. As with loperamide, this does not mean that these agents are not effective in individual patients, but rather that the data supporting their use are weak. Further, these agents can cause a number of dose-related anticholinergic adverse effects, such as constipation, fatigue, dry mouth, dizziness, and blurred vision.5
Peppermint Oil
Although classified as an antispasmodic based on its calcium channel–blocking properties, peppermint oil and its active ingredient, L-menthol, have a number of other effects that may be relevant to IBS, including normalizing orocecal transit time, κ-opioid antagonism, and 5-HT3 antagonism.5,19 In contrast to conventional antispasmodics, a relatively strong body of evidence worldwide supports the use of peppermint oil in IBS. Based on data from 5 RCTs involving 482 patients, the ACG review calculated an RR of 0.51, reflecting a 50% probability of this agent improving IBS symptoms.6
A novel triple-coated formulation of peppermint oil was introduced in the United States subsequent to the publication of the ACG monograph. This formulation is designed to promote sustained release of peppermint oil in the small intestine in an effort to overcome unpredictable delivery and tolerability issues (eg, heartburn, nausea) encountered with older, noncoated formulations.19 In the first RCT evaluating the newer formulation, 72 patients with IBS-D or mixed IBS (IBS-M) were randomized to either the triple-coated formulation or placebo for 4 weeks.19 At the end of the 4 weeks, patients receiving peppermint oil experienced a 40% reduction from baseline in the Total IBS Symptom Score (primary endpoint) compared with a 24.3% reduction among patients receiving placebo (P=.02), with a significant difference between groups noted as early as 24 hours.19 Symptoms associated with viscerosensory perception (abdominal pain/discomfort, bloating, pain at evacuation, and urgency) were more responsive to peppermint oil than motility-related symptoms (constipation, diarrhea, and passage of gas or mucus; Figure 3).
Probiotics
Although probiotics have been studied in a large number of RCTs, evaluating their efficacy in IBS is complicated by the heterogeneity of these studies as well as methodologic problems.6 Further, the large number of preparations included in these studies makes it very difficult to evaluate the efficacy of individual species and strains of probiotics used in IBS. Based on the 23 RCTs evaluated, the ACG monograph made a weak recommendation that probiotics, taken as a whole, improve global symptoms, bloating, and flatulence in IBS.6 However, recommendations regarding individual species, preparations, or strains cannot be made owing to insufficient and conflicting data across studies. As mentioned previously, these conclusions do not indicate that probiotics are not effective in individual patients, but rather that the evidence supporting their efficacy is weak.
Tricyclic Antidepressants
Antidepressant agents have become a widespread treatment for patients with moderate to severe IBS owing to their effects on pain perception, mood, and motility.5,20 Because tricyclic antidepressants (TCAs) have anticholinergic effects and can cause constipation, their use may be most appropriate in IBS-D patients, whereas the prokinetic effects associated with selective serotonin reuptake inhibitors (SSRIs) may be of greater benefit in those with constipation-predominant IBS (IBS-C).21 Although most studies have not differentiated between the various IBS subtypes of the patients recruited, the evidence for the use of TCAs in IBS overall is strong. Based on 11 RCTs involving 744 patients, the ACG monograph concluded that TCAs are effective in relieving IBS symptoms.6 Despite the high quality of evidence, the recommendation was weak based on the potential for adverse effects with these agents.
Alosetron
Alosetron, a selective serotonin 5-HT3 receptor antagonist, has been shown to relieve global IBS symptoms, abdominal pain, urgency, and diarrhea-related complaints in a number of high-quality RCTs involving nearly 5000 patients.6 Despite these robust clinical data, however, the ACG monograph made only a weak recommendation for use of alosetron in female patients with IBS-D based on the potential for adverse events.6 This includes a small but real risk of ischemic colitis (0.95 cases per 1000 patient-years) and serious complications of constipation (0.36 cases per 1000 patient-years).22 Accordingly, alosetron is indicated for a narrow population, specifically, women with severe IBS-D who have not responded to conventional therapies.22,23 Although the use of alosetron continues to be restricted to a risk management program, the program was updated in 2016 to eliminate requirements for a patient attestation form and for affixing prescribing program stickers to alosetron prescriptions.24
Eluxadoline
Eluxadoline is an oral opioid receptor modulator that was approved for use in IBS-D in 2015,25 subsequent to the publication of the ACG monograph on IBS therapies.6 Eluxadoline has mixed effects on opioid receptors that includes µ- and κ-opioid agonism and δ-opioid receptor antagonism.26 The benefits of eluxadoline in IBS are attributed to its effects on µ-opioid rec-eptors, which lead to antimotility effects as well as a reduction in vis-ceral hypersensitivity. The ability of eluxadoline to block peripheral δ-opioid receptors governs its effects on µ-opioid receptors and minimizes development of the constipation that typically results from selective µ-opioid receptor agonists.26
The efficacy of eluxadoline has been demonstrated in 2 pivotal clinical trials involving 2427 patients with IBS-D.26 The primary endpoint used in both trials was a robust, regulatory endpoint defined as the proportion of patients with a composite response of decrease in abdominal pain and improvement in stool consistency on the same day for at least 50% of days from weeks 1 through 12 and weeks 1 through 26. As depicted in Figure 4, both the 75 mg and 100 mg twice-daily doses of eluxadoline achieved this endpoint.26 Further, efficacy was sustained for up to 6 months with the 100 mg twice-daily dose. Although not available at the time of the ACG review, this high-quality evidence lends further support to the efficacy of eluxadoline for the treatment of IBS-D.
Eluxadoline was well-tolerated in the pivotal trials, with a relatively low incidence of constipation underscoring the impact of δ receptor antagonism.26 However, several precautions should be observed when using eluxadoline, based on the potential for an increased risk of sphincter of Oddi spasm and pancreatitis. Importantly, the lower approved dose (75 mg twice daily) should be used in patients without a gallbladder, and these patients should be closely monitored for new or worsening abdominal pain or acute biliary pain with liver or pancreatic enzyme elevations.25 Further, there are a number of contraindications to eluxadoline use, including known or suspected biliary duct obstruction or sphincter of Oddi disease/dysfunction, alcoholism, history of pancreatitis, severe hepatic impairment, and severe constipation or its sequelae.25
Rifaximin
Rifaximin, an oral, nonabsorbable, broad-spectrum antibiotic, is the most extensively evaluated antibiotic in IBS.6 In two large phase 3 trials involving 1260 patients with IBS without constipation (TARGET 1 and 2), a 2-week course of rifaximin 550 mg 3 times daily relieved IBS symptoms, bloating, abdominal pain, and loose or watery stools better than placebo for up to 10 weeks after completion of therapy.27 Based on these data in conjunction with 3 previous RCTs, the ACG monograph made a weak recommendation that rifaximin is effective in reducing total IBS symptoms and bloating in IBS-D.6
Subsequent to the ACG review, however, results of a third pivotal RCT (TARGET 3) evaluating the safety and efficacy of rifaximin repeat treatment were published.28 In this trial, patients who initially responded to 2 weeks of open-label rifaximin but lost response were randomized to treatment with rifaximin or placebo for up to 2 additional repeat treatment courses, separated by 10 weeks (Figure 5).28 The primary endpoint was the proportion of patients who responded according to criteria from the US Food and Drug Administration (FDA), defined as an improvement of 30% or more from baseline in the weekly average abdominal pain score and at least a 50% reduction in the number of days per week with a daily stool consistency of Bristol Stool Scale type 6 or 7. Significant responses to treatment were demonstrated after the first and second treatment phases (Figure 5). Thus, despite the ACG recommendation published in the 2014 monograph, other experts consider the high-quality evidence provided by the complete TARGET clinical program sufficient to support a strong recommendation that rifaximin reduces total IBS symptoms and bloating in IBS-D.
Rifaximin was approved in 2015 for IBS-D at a dose of 550 mg 3 times daily for up to 2 courses of treatment.29 Rifaximin is well-tolerated, with a safety profile similar to that of place-bo. Further, despite concerns regarding the long-term or repeated use of an antibiotic, rifaximin has dem-onstrated an excellent safety profile through-out the time periods that it has been evaluated.6
Evidence-Based Approach to Managing IBS-C and CIC
IBS-C and CIC are considered distinct disorders, distinguished primarily by the presence of abdominal pain as a primary complaint in IBS-C but not CIC.30 However, the symptoms of constipation and IBS-C overlap considerably, and increasingly, it is believed that IBS-C and CIC reside on a spectrum of disease as opposed to being 2 separate and distinct entities.1,31 Accordingly, IBS-C and constipation are often treated similarly,1 although the current evidence base is not always consistent between the disorders (Table 2).
Fiber
Fiber has long been used as first-line therapy for functional bowel symptoms despite a lack of high-quality evidence supporting its use.1 Fourteen RCTs included in the ACG review of fiber in IBS were considered to be of moderate quality, supporting the recommendation that fiber provides overall symptom relief in IBS. However, this recommendation is limited by the potential for fiber to exacerbate bloating, flatulence, and abdominal discomfort.1,6 Further, the benefit is limited to soluble fibers, most notably psyllium.6,32 In the largest study to date, 275 adults with IBS were randomized to soluble fiber (psyllium), insoluble fiber (bran), or placebo once daily for 12 weeks.33 Psyllium was found to be significantly more effective than placebo in providing adequate symptom relief in the first 2 months of therapy, whereas bran was not more effective than placebo.33 Importantly, early drop-out was considerable in the bran group, most commonly owing to exacerbation of IBS. This underscores issues of tolerability and the need to initiate therapy with a low dose and gradually titrate upwards to improve tolerability.5 Review of this study and the other 6 RCTs led the ACG to make a weak recommendation for psyllium, but not bran, to provide overall symptom relief in IBS.6 Although the evidence indicates that symptoms may improve in as few as 6% of patients (based on the upper limit of the 95% CI), psyllium is considered a safe and cost-effective approach for patients with IBS-C.
The evidence for the efficacy of fiber in CIC is less robust than in IBS-C, with only 3 RCTs, involving fewer than 300 patients, reviewed in the ACG monograph.6 However, the strong RR (0.25) calculated from these studies supports a strong recommendation that fiber can increase stool frequency in patients with CIC.
Stimulant Laxatives
Stimulant laxatives (senna, bisacodyl, castor oil, cascara, rhubarb, and aloe) produce bowel movements by promoting fluid and electrolyte secretion by the colon or by inducing colonic peristalsis.6 Despite their long history of use in constipation, only 2 RCTs with bisacodyl and sodium picosulfate were evaluated in the ACG monograph.6,34,35 However, the quality of these data were considered moderate, leading to a strong recommendation that sodium picosulfate and bisacodyl are effective in CIC. Tolerability can be an issue with these agents, particularly with regard to diarrhea and abdominal cramping. There is insufficient evidence to recommend the use of other stimulant laxatives for chronic constipation, and similarly, there are no RCTs of stimulant laxatives in IBS-C.5,6
Polyethylene Glycol
Despite robust evidence for efficacy in CIC, the benefit of the osmotic laxative polyethylene glycol (PEG) in IBS-C is less clear. Based on 4 high-quality RCTs, the ACG recognizes the efficacy of PEG in increasing stool frequency and consistency in CIC.6 In contrast, only 2 RCTs, one in adolescents and another in adults in Europe, have studied PEG in IBS-C.36,37 Although both trials demonstrated improvement in stool frequency, neither study demonstrated pain relief or reduction in overall symptoms in IBS. Based on this low-quality evidence, the ACG has issued a weak recommendation regarding the use of PEG in IBS-C.6
Selective Serotonin Reuptake Inhibitors
SSRIs are commonly used in IBS-C owing to their prokinetic effects as well as their visceral analgesic effects (although these effects are less strong than those of TCAs).5,20 Like TCAs, high-quality evidence supports the efficacy of SSRIs in relieving IBS symptoms.6 However, the benefit of these agents can be limited by adverse effects, as well as the length of time required to achieve an effect. Indeed, 4 to 8 weeks may be needed to observe maximal response.20,38
Lubiprostone
Approved for the treatment of IBS-C in 2006,39 lubiprostone is a locally acting, bicyclic functional fatty acid derived from prostaglandin E1 that acts by specifically activating CIC-2 chloride channels on the apical aspect of enterocytes, eliciting a chloride-rich fluid secretion.40 Combined analysis of two large, 12-week, phase 3 trials demonstrated that this agent significantly improved symptoms of IBS-C compared with placebo (17.9% overall responders vs 10.1%; P=.001).41 It also improved abdominal pain. To determine overall responders at 12 weeks, these trials used a rigorous primary endpoint: at least moderate relief for 4 of 4 weeks or significant relief for 2 of 4 weeks. An extension study of patients in these trials demonstrated that initial improvements were maintained throughout 9 to 13 months of treatment.42 Based on these data, the ACG issued a strong recommendation regarding the efficacy of lubiprostone for the treatment of IBS-C.6 High-quality evidence also supports the use of lubiprostone in CIC, with efficacy demonstrated in 4 RCTs involving 651 patients.6
Lubiprostone is approved in dosages of 8 µg twice daily and 24 µg twice daily for IBS-C and CIC, respectively.39 The most common adverse effect with lubiprostone is dose-related nausea, occurring in 8% and 29% of patients receiving 8 µg and 24 µg twice daily, respectively, in pivotal trials of IBS-C and CIC (compared with 4% and 3% of patients receiving placebo).39,41 Lubiprostone should be taken with food and water to minimize nausea.5,39 Additionally, therapy can be initiated at lower doses and titrated upward as needed.
Guanylate Cyclase Agonists
Linaclotide
Linaclotide, a first-in-class guanylate cyclase agonist, was approved for the treatment of IBS-C in 2012.43 The efficacy of this agent is supported by 3 RCTs involving 2028 patients, considered to be high-quality evidence at low risk of bias by the ACG review.6 The 2 linaclotide pivotal RCTs were the first studies to use the FDA-defined composite endpoint, a rigorous endpoint defined as achieving at least 30% reduction in the worst abdominal pain each week and an increase in 1 or more complete spontaneous bowel movements (SBMs) from baseline for at least 6 of 12 weeks.44,45 Although improvement in stool frequency occurs within a week of treatment initiation, maximal improvement in abdominal pain and bloating may take up to 8 to 12 weeks.5 Additional analyses of the pivotal data have demonstrated that linaclotide significantly improved all abdominal symptoms, global measures, and IBS-related quality of life in subpopulations of IBS-C patients with severe abdominal symptoms.46
Like IBS-C, the efficacy of lin-aclotide in CIC is supported by high-quality evidence from 3 RCTs and a strong recommendation from the ACG.6 Further, results of a phase 3b RCT published subsequent to the ACG monograph demonstrated efficacy of linaclotide in improving abdominal bloating in patients with CIC.47 In this 12-week study involving 483 patients with Rome II–defined chronic constipation and significant abdominal bloating, linaclotide doses of 145 µg and 290 µg daily significantly improved bowel symptoms and bloating compared with placebo (Figure 6). Given that abdominal bloating is present in a majority of patients with CIC and is considered to be the most bothersome symptom of constipation, the efficacy of linaclotide in improving bloating is important.47
Linaclotide is approved at a dosage of 145 µg once daily for CIC and 290 µg once daily for IBS-C.43 The most common adverse effect associated with its use is diarrhea, reported in up to 20% of patients taking the higher dose (290 µg).43 This can be managed by administering the agent 30 to 60 minutes before breakfast,5,45 and/or by initiating therapy with
the lower dose and titrating upwards as needed.
Plecanatide
Plecanatide is an oral, locally acting guanylate cyclase agonist that is being studied for use in CIC and IBS-C.1,17,48 The results of two large phase 3 RCTs have recently demonstrated the efficacy of this agent in improving CIC.49,50 In these studies, plecanatide doses of 3 mg and 6 mg significantly improved the proportion of durable complete SBM responders, defined as patients who were weekly responders for at least 9 of 12 treatment weeks, including at least 3 of the last 4 weeks (Figure 7). Improvements in complete SBM and SBM occurred within 1 week of therapy and lasted throughout the 12 weeks of the trials. Like linaclotide, the most frequent adverse effect observed with plecanatide is diarrhea, which is typically mild and leads to few treatment discontinuations. The FDA approved plecanatide for CIC in January 2017.51
Conclusions
With the growing evidence base for IBS and CIC therapies, it has become increasingly important for clinicians to assess the quality of evidence and understand how to apply it to the care of individual patients. Emerging evidence supports a primary role of diet, particularly the low-FODMAP diet, in some patients with IBS-D. Of the common medical therapies for IBS-D, the best clinical trial evidence supports the use of alosetron, TCAs, peppermint oil, eluxadoline, and rifaximin. Although IBS-C and CIC are often treated similarly, the evidence for various therapies shows some differences across conditions. Whereas PEG and stimulant laxatives are effective nonprescription therapies for CIC, there is no evidence from RCTs demonstrating their efficacy in reducing global symptoms in IBS-C. In contrast, high-quality evidence supports the efficacy of lubiprostone and linaclotide in both CIC and IBS-C. The successful application of evidence-based medicine requires that clinicians integrate their understanding of the evidence with their own clinical experience in order to balance the magnitude of benefit and risk for individual patients.
Disclosure
Dr Chey has received consultant/research support from Ardelyx, Ironwood Pharmaceuticals, Inc., and Vibrant. He is a consultant for Allergan, Inc., Ardelyx, IM HealthScience, Ironwood Pharmaceuticals, Inc., Prometheus, QOL Medical, Salix/Valeant Pharmaceuticals, and Vibrant. He has received honoraria from Ardelyx, IM HealthScience, Ironwood Pharmaceuticals, Inc., Prometheus, QOL Medical, and Salix/Valeant Pharm-a-ceuticals. He has received other fin-an-cial material support from CMO and My Total Health.
References
1. Eswaran S, Guentner A, Chey WD. Emerging pharmacologic therapies for constipation-predominant irritable bowel syndrome and chronic constipation. J Neurogastroenterol Motil. 2014;20(2):141-151.
2. Higgins PDR, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol. 2004;99(4):750-759.
3. Saito YA, Schoenfeld P, Locke GR III. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002;97(8):1910-1915.
4. Chang L, Lembo A, Sultan S. American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome. Gastroenterology. 2014;147(5):1149-1172.e2.
5. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313(9):949-958.
6. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(suppl 1):S2-S26; quiz S27.
7. American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(suppl 1):S1-S35.
8. Brandt LJ, Prather CM, Quigley EMM, Schiller LR, Schoenfeld P, Talley NJ. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol. 2005;100(1)(suppl 1):S5-S21.
9. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002;97(11)(suppl):S7-S26.
10. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926.
11. Young JM, Solomon MJ. How to critically appraise an article. Nat Clin Pract Gastroenterol Hepatol. 2009;6(2):82-91.
12. Practice Committee of American Society for Reproductive Medicine. Interpretation of clinical trial results. Fertil Steril. 2008;90(5)(suppl):S114-S120.
13. Gupta SK. Intention-to-treat concept: a review. Perspect Clin Res. 2011;2(3):109-112.
14. Williams JK. Understanding evidence-based medicine: a primer. Am J Obstet Gynecol. 2001;185(2):275-278.
15. Halpert A, Dalton CB, Palsson O, et al. What patients know about irritable bowel syndrome (IBS) and what they would like to know. National Survey on Patient Educational Needs in IBS and development and validation of the Patient Educational Needs Questionnaire (PEQ). Am J Gastroenterol. 2007;102(9):1972-1982.
16. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67-75.e5.
17. Halland M, Saito YA. Irritable bowel syndrome: new and emerging treatments. BMJ. 2015;350:h1622.
18. Eswaran SL, Chey WD, Han-Markey T, Ball S, Jackson K. A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D. Am J Gastroenterol. 2016;111(12):1824-1832.
19. Cash BD, Epstein MS, Shah SM. A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms. Dig Dis Sci. 2016;61(2):560-571.
20. Dekel R, Drossman DA, Sperber AD. The use of psychotropic drugs in irritable bowel syndrome. Expert Opin Investig Drugs. 2013;22(3):329-339.
21. Ford AC, Quigley EMM, Lacy BE, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(9):1350-1365.
22. Chang L, Chey WD, Harris L, Olden K, Surawicz C, Schoenfeld P. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol. 2006;101(5):1069-1079.
23. Lotronex [package insert]. Prometheus Laboratories: San Diego, CA; 2014.
24. US Food and Drug Administration. Approved risk evaluation and mitigation strategies (REMS). Lotronex (alosetron hydrochloride). FDA.gov. https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=29. Updated April 29, 2016. Accessed January 9, 2017.
25. Viberzi [package insert]. Actavis Pharma, Inc: Parsipanny, NJ; 2015.
26. Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med. 2016;374(3):242-253.
27. Pimentel M, Lembo A, Chey WD, et al; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22-32.
28. Lembo AJ, Pimentel M, Rao SS. Efficacy and safety of repeat treatment with rifaximin for diarrhea-predominant irritable bowel syndrome (IBS-D): results of the TARGET-3 study. Paper presented at: the 2014 Annual Scientific Meeting of the American College of Gastroenterology; October 17-22, 2014; Philadelphia, PA. Abstract 45.
29. Xifaxan [package insert]. Salix Pharmaceuticals: Bridgewater, NJ: 2015.
30. Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393-1407.
31. Heidelbaugh JJ, Stelwagon M, Miller SA, Shea EP, Chey WD. The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden. Am J Gastroenterol. 2015;110(4):
580-587.
32. Moayyedi P, Quigley EMM, Lacy BE, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(9):1367-1374.
33. Bijkerk CJ, de Wit NJ, Muris JWM, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ. 2009;339:b3154.
34. Mueller-Lissner S, Kamm MA, Wald A, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol. 2010;105(4):897-903.
35. Kamm MA, Mueller-Lissner S, Wald A, Richter E, Swallow R, Gessner U. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Clin Gastroenterol Hepatol. 2011;9(7):577-583.
36. Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol. 2013;108(9):1508-1515.
37. Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2006;23(1):191-196.
38. Grover M, Drossman DA. Centrally acting therapies for irritable bowel syndrome. Gastroenterol Clin North Am. 2011;40(1):183-206.
39. Amitiza [package insert]. Sucampo Pharma Americas, LLC: Bethesda, MD; 2013.
40. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008;103(1):170-177.
41. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome—results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29(3):329-341.
42. Chey WD, Drossman DA, Johanson JF, Scott C, Panas RM, Ueno R. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2012;35(5):587-599.
43. Linzess [package insert]. Forest Pharmaceuticals, Inc: Cincinnati, OH; 2015.
44. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107(11):1714-1724.
45. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107(11):1702-1712.
46. Rao SSC, Quigley EMM, Shiff SJ, et al. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation. Clin Gastroenterol Hepatol. 2014;12(4):616-623.
47. Lacy BE, Schey R, Shiff SJ, et al. Linaclotide in chronic idiopathic constipation patients with moderate to severe abdominal bloating: a randomized, controlled trial. PLoS One. 2015;10(7):e0134349.
48. Shailubhai K, Comiskey S, Foss JA, et al. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci. 2013;58(9):2580-2586.
49. Miner PB, Prieto B, La Portilla De M, et al. A phase III study of the efficacy and safety of plecanatide in the treatment of Chronic Idiopathic Constipation (CIC) (Study-00) [DDW abstract SA1440]. Gastroenterology. 2016;150(4)(suppl 1):S316.
50. Miner PB, Lentz JD, Berenguer R, et al. Efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation (CIC): results from a multicenter phase III study (Study-03) [DDW abstract SA1444]. Gastroenterology. 2016;150(4)(suppl 1):S316.
51. FDA approves Trulance for chronic idiopathic constipation. Fda.gov. Published July 15, 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm537725.htm. Posted January 19, 2017. Accessed January 26, 2017.